Home > Insider Trading > Amgen Inc

Amgen Inc (AMGN)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
211 - 220
Next >>

Healthcare Hedge Fund Orbimed's Top Picks and New Move

According to a Schedule 13D form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by about...

Keep Reading →

March 26th, 2015 - Hedge Funds News

Gilead Sciences, Inc., Amgen, Inc., Biogen Idec Inc Among Billionaires' 5 Hottest Biotech Picks

With the high volatility prevalent in the biotechnology sector, investors have a hard time picking the right stocks to invest in.

Keep Reading →

February 23rd, 2015 - Hedge Funds News

Ariad Pharmaceuticals, Inc., Quest Diagnostics Inc, Amgen, Inc.: Sarissa Capital's Top Stock Picks and New Moves

Alex Denner’s Sarissa Capital Management recently disclosed its stock picks for the fourth quarter of 2014 in a 13F Form filed with the U.S. Securities and Exchange Commission.

Keep Reading →

February 21st, 2015 - Hedge Funds News

Billionaire Dan Loeb`s Third Point Looks to Rebound From Poor Year With Top Picks: Alibaba Group Holding Ltd (BABA), Amgen, Inc. (AMGN), Dow Chemical Co (DOW)

Dan Loeb`s Third Point filed its latest 13F with the SEC last week, detailing its long positions at the end of a self-admittedly poor year for the fund.

Keep Reading →

February 15th, 2015 - Hedge Funds News

Amgen, Inc. (AMGN)’s Drug Trial Fails To Live Up To Expectation

Shares of Amgen, Inc.

Keep Reading →

August 14th, 2014 - News

Amgen, Inc. (AMGN) Announces Revenue Growth And Profitability In The Second Quarter

Amgen, Inc. (NASDAQ:AMGN) announced its second quarter financial results on July 29, 2014. Amgen's total revenues increased by 11% on the year to $5.18 billion.

Keep Reading →

July 30th, 2014 - Earnings Report News